Investments Life Sciences
Committed to Quality of Life
With an aging world population, a rising interest in personal health management, increased amounts of disposable income, and the access to up-to-date information afforded by the Internet – life extension and quality of life improvement are primary motivators in the Life Sciences market, and the driving force behind GlenRock's Life Sciences investment strategy.
Investing in Tomorrow's Pioneers
With the right combination of a highly-developed medical community, world-class scientific resources, and excellent technological capabilities, Israel has produced numerous commercial Life Sciences success stories. GlenRock identifies and invests in cutting-edge Israeli Life Sciences technology at all stages of commercialization – from ideas on paper to viable companies breaking new ground in the fields of medical devices and biotechnology.
GlenRock is exploring investments in the Cannabis space.
Rainbow Medical Innovation
A private investment company, which aims to seed and grow companies, mostly invented by the serial entrepreneur Yossi Gross, that develop breakthrough medical device-based therapeutic platforms addressing significant unmet market need and leads them to becoming high value companies.
Rainbow Medical is committed to generating returns from its portfolio of cutting edge medical device technologies in a diverse range of medical fields. Among Rainbow's investors are major players in the industry as Medtronic and Abbott and the Kirsh Group. Rainbow assists the portfolio companies from seeding through obtainment of European CE Mark and an FDA. leading portfolio companies are Vascular Dynamics, Bluewind, Nano Retina, Chronisense and Enopace, some have entered into First in Man clinical studies.
Latest News (12/2019): Rainbow invested more than $200M and lately raised $80M from insiders, led by the Kirsh Group.
Latest News (12/2019): The company was acquired in 2017 by Edwards Lifesciences (NYSE:EA) for $790M and is now focused on its spinoff MitralTech.
Kamada (NASDAQ:KMDA), (TASE:KMDA)
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a
commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary
platform technology and know-how for the extraction and purification of proteins from human plasma to
produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived
Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered
therapeutic roles given its immunomodulatory anti-inflammatory, tissue-protective and antimicrobial
properties. The Company's flagship product is GLASSIA@, the first liquid, ready-to-use, intravenous
plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets
GLASSIA@ in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited
and in other counties through local distributors. Kamada's second leading product is KamRAB, a rabies
immune globulin (Human) for Post-Exposure Prophylaxis against rabies infection. KamRAB is FDA
approved and is being marketed in the U.S. under the brand name KEDRAB and through a strategic
partnership with Kedrion S.p.A. In addition to GLASSIA and KEDRAB, Kamada has a product line of
four other plasma-derived pharmaceutical products administered by injection or infusion, that are
marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other
countries in Latin America and Asia. Kamada has late-stage products in development including an
inhaled formulation of AAT for the treatment of AAT deficiency, and in addition, its intravenous AAT
is in development for other indications, such as GvHD, prevention of lung transplant rejection and type-1
diabetes. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics
market by distributing more than 20 complementary products in Israel that are manufactured by third
Latest News (12/2019): The company expects to meet its full year 2019 total revenues guidance of $125M to $130M. First nine months revenue was $95.1 and net income was $16.9M. The PE Fund FIMI acquired 31% of the company.
The company plans to utilize its Hyper-Immunoglobulin (IgG) Platform Technology to evelop an Anti-Corona (COVID-19) Immunoglobulin as a potential therapy for Severely Ill Coronavirus Patients.
Evogene (NYSE:EVGN), (TASE:EVGN)
Is an agro-biotechnology company specializing in the development of superior crops through genome remodeling. Evogene's solutions are based on the tight integration of patented technologies and expertise in computational genomics, functional genomics and advanced high throughput plant breeding. Evogene's core technology platform mimics and accelerates evolutionary processes and can address concerns associated with transgenic plants.
The company announced a strategic collaboration with Monsanto (NYSE: MON) one of the worldwide leading seed companies. Additional collaborations were established with Bayer CropScience, DuPont, Biogemma and other leading companies. Evogene is also collaborating with the Chinese Biotechnology company DBN. the subsidiaries and divisions include the following activities: AgPlenus - focusing on the development of novel herbicides and insecticides. Lavie-bio - focused on bio-stimulants and bio-pesticides. Ag-Seeds division, focusing on (a) insect control seed traits, (b) yield & abiotic stress and (c) disease resistance seed traits. Biomica - focused on developing therapeutics based on microbes and small molecules. Canonic - focusing on developing medical grade cannabis products through a plant genomic approach.
Latest News (12/2019): The company completed a restructuring process where by Evogene is now a parent company to subsidiaries which demonstrates Evogene's potential to penetrate different industries based on its CPR engine. Lavie Bio raised$10M from Corteva as well as shares of Taxon Biosciences. Post transaction Evogen's share in Lavie Bio is 72%. Other subsidiaries are in the process of raising funds.
Enzymotec (NASDAQ:ENZY) (previous portfolio company)
The company completed listing on NASDAQ in 2013.
Rosetta Genomics (NASDAQ: ROSG) (previous portfolio company)
The company completed listing on NASDAQ in 2007.
Vascular Biogenics (NASDAQ: VBLT)
VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements. Lead candidate is VB-111, a gene-based biologic agent for solid tumor indications which was advanced to programs for recurrent glioblastoma, ovarian cancer and thyroid cancer.
Latest News (12/2019): VBL announced positive outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer pivotal study. Pivotal Phase 3 in rGBM is ongoing under a special protocol assessment granted by the FDA.
LifeBond (previous portfolio company)
Develops a novel technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier.
The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.
Latest News (12/2019): The company completed mega clinical trials in India, Germany, Israel and Hungary and awaiting FDA approval.
Is specializing in the field of gastroenterology and GI endoscopy. SMART's products address key challenges in concurrent endoscopy, and facilitates enhanced capabilities and range of standard endoscopes in a variety of endoscopy procedures.
Latest News (12/2019): The company sales are gaining momentum worldwide.
Bioness (previous portfolio company)
Visionsense (previous portfolio company)
Is positioning itself as a high-end technology company, aiming to drive the Minimally Invasive Surgery ("MIS") visualization market from 2-Dimensional optics to "smart" 3-Dimensional sensors. The company received FDA and CE approvals for its 3DHD system and is a leading player in 3D visualization in minimally invasive surgery.
Latest News (12/2019): The company was acquired by Medtronic for $75M.
Is a medical device company that developed the SurroundScope System, an innovative laparoscopic camera system. The SurroundScope System is the first laparoscopic system to offer a 270-degree field-of-view. The SurroundScope received FDA clearance.
Latest News (12/2019): The company is raising funds to support market penetration and its next generation of products.
Yossi Gross is a serial entrepreneur in the field of advanced technologies for medical devices.
Yossi has established 15 companies thus far, in most of which GlenRock has invested, including:
EarlySense - EarlySense has introduced an innovative continuous patient monitoring solution designed to enhance patient safety and reduce risk for general care patients. the company focused on next generation patient monitoring systems for hospitals, healthcare systems, integrated delivery networks and rehabilitation centers.
Latest News (12/2019): The company partnered with "American Well" to provide Telehealth Services powered by smart sensors.
BrainsGate - See above for detail information about the company.
Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.
Latest News (12/2019): The company completed First in Man.